Plasma homoarginine and outcomes data were available for 3514 DHS participants. The cohort consisted of 56% women; the median age of the cohort was 43 (interquartile range, 36-52) years. The study comprised 52% blacks, 29% whites, and 17% Hispanics. Median plasma homoarginine was 2.80 (interquartile range, 2.14-3.54) μmol/l. The baseline © 2014 American Heart Association, Inc. Objective-The nonproteinogenic amino acid homoarginine has been postulated to have antiatherosclerotic effects as a weak substrate of nitric oxide synthase. This investigation in the population-based Dallas Heart Study (DHS) aimed to evaluate the association of homoarginine with clinical and subclinical cardiovascular outcomes. Approach and Results-Plasma homoarginine was measured in 3514 participants of the DHS using liquid chromatographytandem mass spectrometry. Associations between homoarginine and major adverse cardiovascular events and all-cause mortality were analyzed using Cox proportional hazard models adjusting for cardiovascular risk factors. linear regression was used to assess cross-sectional associations between homoarginine and subclinical cardiovascular disease, including coronary artery calcium measured by electron beam-computed tomography, and aortic plaque burden and aortic wall thickness by MRI. Median age was 43 (interquartile range, 36-52) years, with 56% women and 52% black participants. Median follow-up was 9.4 (9.0-9.8) years. Median plasma homoarginine was 2.80 (2.14-3.54) μmol/l. In multivariable models, higher homoarginine was associated with lower rate of major adverse cardiovascular events (hazard ratio, 0.86; 95% confidence interval, 0.75-0.98) and lower all-cause mortality (hazard ratio, 0.82; 0.73-0.92; per 1 log SD increase in homoarginine). Homoarginine was inversely and independently associated with aortic wall thickness (β-estimate, −0.04; P<0.01) but not with aortic plaque burden and coronary artery calcium. Conclusions-Homoarginine is inversely associated with subclinical vascular disease and with risk for cardiovascular disease events. Additional studies are needed to evaluate whether the regulation of plasma homoarginine could emerge as a novel therapeutic option to improve outcomes in cardiovascular disease. 
H omoarginine is a naturally occurring nonproteinogenic amino acid structurally related to l-arginine. Homoarginine has been postulated to be an antiatherosclerotic factor because it is a weak substrate for nitric oxide (NO) synthase and can, therefore, be converted to NO. 1 Experimental studies have shown that exogenous homoarginine exerts antihypertensive and antithrombotic effects. 2, 3 Recently, clinical data suggested a role of low endogenous homoarginine as a risk marker for cardiovascular and cerebrovascular events. [4] [5] [6] Importantly, in contrast to other cardiovascular biomarkers, such as N-terminal brain natriuretic peptide or asymmetrical dimethylarginine that are positively associated with cardiovascular outcomes, 7, 8 plasma concentrations of homoarginine were found to be inversely associated with cardiovascular and all-cause mortality in patients at risk. [4] [5] [6] [9] [10] [11] [12] In addition, experimental studies in mice have supported a mechanistic link between low homoarginine and cerebrovascular disease. 10 To further explore the potential role of homoarginine in the development of cardiovascular disease (CVD), we measured plasma homoarginine in the multiethnic, population-based Dallas Heart Study (DHS), to investigate (1) the associations of homoarginine with cardiovascular outcomes in the general population and (2) a potential relationship with subclinical disease measures. characteristics of the entire cohort are presented in Table 1 
Factors Associated With Circulating Homoarginine
Unadjusted correlation analyses for circulating homoarginine are provided in Table I in the online-only Data Supplement. The strongest correlations with homoarginine were seen for l-arginine, cystatin C, and several anthropometric measures (eg, lean mass and body mass index [BMI]). No correlation was found between plasma homoarginine and the methylated arginine derivatives asymmetrical dimethylarginine and symmetrical dimethylarginine. In addition, a weak association was observed between homoarginine and endothelial cellselective adhesion molecule but not with vascular cell adhesion molecule 1 or intercellular adhesion molecule 1. In a multivariable linear regression model, log-homoarginine was independently and positively associated with sex, black race, BMI, estimated glomerular filtration rate, and hypertension and inversely associated with current smoking status, diabetes mellitus, and history of stroke (Table II in 
Association of Homoarginine With Cardiovascular Outcomes
During a median follow-up of 9.4 (9.0-9.8) years, 184 individuals experienced major adverse cardiovascular events (MACE), including 81 cardiovascular deaths, 51 nonfatal strokes, or 52 nonfatal myocardial infarctions. To assess the effect of homoarginine on MACE across the range of circulating homoarginine, restricted cubic spline curves were constructed. Continuous analyses using the homoarginine median as the cut point revealed high hazards at low circulating homoarginine, splaying upward above the homoarginine median ( Figure 1 ). In Cox regression analyses, adjusted for age, sex, and race, an increase of 1 SD log plasma homoarginine (0.4; antilog=1.49 μmol/l) was associated with a hazard reduction of 16% for the MACE end point (model 1, Table 2 ). Similar results were obtained in the fully adjusted model (model 4; Table 2 ). (Figure 2 ). In the fully adjusted model of Cox regression analyses, an increase of 1 log SD homoarginine (0.4; antilog=1.49 μmol/l) revealed a significant hazard reduction of 18% for overall mortality (model 4; Table 2 ).
Relation of Homoarginine to Mortality

Association Between Homoarginine and Subclinical CVD Measures
In age, sex, and race-adjusted linear regression analyses, log-homoarginine was inversely associated with aortic wall thickness (AWT; 
Homoarginine, BMI, and AGAT Single Nucleotide Polymorphism rs1288775
Associations between plasma homoarginine levels and the candidate single nucleotide polymorphism rs1288775 were analyzed. Genotype frequencies at the AGAT 1288775 locus significantly differed between the investigated ethnic groups. A majority of black participants were AA carriers (Table 4) . In Hispanic individuals, the majority carried the heterozygous AT genotype. In contrast, only 8% of the white participants are homozygous for the AA genotype. However, regardless of the genotype frequency, in each race/ethnic group, the homoarginine plasma concentration decreased from AA to TT allele carriers (Table 4 ). In the overall population, as well as in black and Hispanic individuals, the BMI also decreased from AA to TT carriers (Table 4) .
Discussion
There are several novel findings from this study. First, homoarginine is inversely associated with MACE. Second, low homoarginine predicts all-cause mortality in the general US population; third, circulating homoarginine shows an inverse association with AWT; and finally, genetic variations within the AGAT gene are linked to homoarginine levels and higher BMI.
Preliminary evidence suggests potential use of the l-arginine derivative homoarginine as a prognostic marker for adverse cardiovascular events in patients at increased cardiovascular risk. Results from several studies showed an independent association between homoarginine levels and markers of bone metabolism, 13, 14 CVD (ie, sudden cardiac death, heart failure, and myocardial infarction), cerebrovascular outcome, and mortality (both all-cause and cardiovascular) in these at risk patients. [4] [5] [6] [9] [10] [11] [12] Interestingly, in contrast to other biomarkers related to the l-arginine pathway, such as asymmetrical dimethylarginine 15 and symmetrical dimethylarginine, 16 homoarginine was inversely associated with outcome in these Data are presented as median (interquartile range), or n (%), as appropriate. ACE indicates angiotensin-converting enzyme; ADMA, asymmetrical dimethylarginine; APB, aortic plaque burden; AWT, aortic wall thickness; BP, blood pressure; CAC, coronary artery calcium; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; ESAM, endothelial cell-selective adhesion molecule; HDL-C, high density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment-insulin resistance; hs-cTnT, high sensitivity-cardiac troponin T; hs-CRP, high sensitivity-C reactive protein; ICAM-1, intercellular adhesion molecule 1; LDL-C, low density lipoprotein cholesterol; MACE, major adverse cardiovascular events; NTproBNP, N-terminal brain natriuretic peptide; SDMA, symmetrical dimethylarginine; and VCAM-1, vascular cell adhesion molecule 1.
*P values provided for MACE vs no MACE, or died vs not died, respectively.
patients. In our population-based cohort, median homoarginine plasma concentration was higher (ie, 2.8 μmol/l) when compared with the cardiovascular cohorts we have reported previously (ie, 1.07 μmol/l in patients with ischemic stroke 10 and 1.78 μmol/l in patients with heart failure). 9 In addition, plasma homoarginine was independently and inversely associated with cardiovascular outcome and all-cause mortality in the DHS population. These findings suggest a potential protective role of homoarginine in the pathogenesis of CVD.
Recent results from genome-wide association studies identified a strong link between plasma homoarginine and the enzyme l-arginine:glycine-amidinotransferase (AGAT). 10, 17 Mice with genetic deletion of AGAT have low plasma homoarginine levels. 10 Supporting the clinical data, we have previously reported an inverse correlation between homoarginine and stroke severity in this mouse model. Of particular note, this phenotype was reversible by homoarginine supplementation, suggesting a causal link between homoarginine and stroke pathogenesis. 10 Although the underlying mechanism linking homoarginine with cardiovascular risk remains poorly understood, involvement in NO generation is plausible 18 because homoarginine is both a substrate for NO synthase 1, 19 and a weak inhibitor of arginase activity. 19 By inhibiting arginase, homoarginine can increase the availability of the NO precursor l-arginine. 20 NO features antiatherosclerotic properties modulating the release of proinflammatory cytokines, as well as the adhesion and infiltration of immune cells. Previous studies observed an inverse correlation of homoarginine with intercellular adhesion molecule 1 and vascular cell adhesion molecule 1. 4 Although this association was not supported in the present study, we found a higher concentration of the adhesion molecule endothelial cell-selective adhesion molecule in individuals with lower homoarginine. Endothelial cell-selective adhesion molecule is involved in the transmigration process of neutrophils through the endothelial layer, suggesting that homoarginine might prevent not only monocyte adhesion but also transmigration of neutrophils. 21 Of note, we found an independent positive association between circulating homoarginine and AWT. Previous investigations of the DHS identified AWT, but not aortic plaque burden, as a significant independent predictor of composite cardiovascular events. 22 AWT is thought to be an early measure of subclinical atherosclerosis, supporting the link between homoarginine to endothelial dysfunction. 22 In contrast, we did not observe a cross-sectional association with coronary calcification, which reflects a more advanced phase of atherosclerosis compared with aortic wall thickening. 23 AGAT is mainly expressed in the kidney and, in addition to the formation of homoarginine from l-arginine, is also the rate-limiting enzyme in creatine biosynthesis. 10, 24, 25 We and others have reported a positive correlation between plasma homoarginine and its precursor l-arginine, as well as with creatinine, the breakdown product of creatine ( function, as indicated by low estimated glomerular filtration rate or high cystatin C, was related to low plasma concentrations of homoarginine in our study (Table I in the online-only Data Supplement), presumably as a consequence of low renal AGAT activity. It is notable that in contrast to the inverse associations between homoarginine and adverse cardiovascular outcome, we observed positive associations between circulating homoarginine and multiple CVD risk factors, including hypertension, obesity, insulin resistance, and dyslipidemia (Tables I and II in the online-only Data Supplement) . Although an explanation for these apparently contradictory findings is still lacking, they are concordant with recent results obtained from the Hoorn Study, in which, despite a strong positive correlation of circulating homoarginine with systolic and diastolic blood pressure, 29 low plasma homoarginine emerged as an independent predictor for all-cause and cardiovascular mortality. 27 One possible explanation for these findings is that homoarginine increases in response to risk factors, such as obesity or hypertension but then attenuates, to some extent, their adverse cardiovascular influence. Evidence from animal models also indicates a positive association between homoarginine and metabolic parameters that are traditionally associated with CVD risk. For example, our group has recently published data showing that creatine-and homoarginine-deficient AGAT knockout mice are protected from diet-induced obesity. 24 This metabolic phenotype was normalized on creatine supplementation, suggesting a homoarginine-independent effect. In line with this observation, results from the present study revealed an independent and inverse association between circulating homoarginine and AWT, despite greater risk factor burden. At this point, additional studies are required to explore and elucidate this mechanistic link.
Candidate single nucleotide polymorphism analyses in the present study revealed a graded association between plasma homoarginine and the AGAT single nucleotide polymorphism rs1288775, a known missense mutation within the AGAT gene accounting for an A→T (Gln110His) exchange. 10, 17 Among all ethnic groups, AA carriers had the highest and TT carriers the lowest homoarginine plasma concentrations (Table 4 ). In line with previous experimental and epidemiological evidence, 10 these data suggest that plasma homoarginine is, at least partly, dependent on genetic variants of the AGAT gene, and moreover, irrespective of ethnic background. In addition, in our investigated US population this genotype *Model 1 adjusted for age, sex, and race; model 2 adjusted for variables in model 1 plus diabetes mellitus, body mass index, hypertension, hypercholesterolemia, current smoking, and history of myocardial infarction, congestive heart failure, or stroke, and medication (statin, β-blocker, and angiotensin-converting enzyme inhibitor). Model 3 adjusted for variables in model 2 plus glomerular filtration rate estimated using the Chronic Kidney Disease-Epidemiology Collaboration formula, and symmetrical dimethylarginine. Model 4 adjusted for variables in model 3 plus log-transformed values of high-sensitivity C-reactive protein, pro-brain-type natriuretic peptide, and cardiac troponin T. AGAT indicates L-arginine:glycine-amidinotransferase; BMI, body mass index; and SNP, single nucleotide polymorphism.
*Data presented as median (interquartile range).
seems to associate with not only circulating homoarginine concentrations but also higher BMI. This genetic link may, at least in part, explain the close correlation observed between homoarginine and BMI (Tables I and II in the online-only  Data Supplement) . limitations of this study include a low frequency of events in our population-based sample, the availability of only single measurements of homoarginine and other covariates at baseline, and that previous CVD was self-reported information. The relatively low frequency of clinical events did not allow race-specific genotype-outcome analyses. Because the statistical analyses do not account for over sampling of blacks, the findings may not be generalizable to populations with different race/ethnic composition.
In summary, our findings in a large multiethnic populationbased cohort identified an independent inverse association of circulating homoarginine with MACE and with all-cause mortality in the general US population. In addition, we observed an inverse association between homoarginine and AWT, suggesting a potential protective role of homoarginine in early atherosclerosis as underlying mechanism for cardiovascular events. In-depth investigations are now needed to prove causality.
